Filing Details
- Accession Number:
- 0000874716-24-000017
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-09 17:03:55
- Reporting Period:
- 2024-02-08
- Accepted Time:
- 2024-02-09 17:03:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1521861 | George Fennell | One Idexx Drive Westbrook ME 04092 | Svp, Chief Revenue Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-08 | 1,612 | $62.00 | 6,712 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-02-08 | 8,198 | $62.00 | 14,910 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-08 | 1,209 | $572.14 | 13,701 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-08 | 2,279 | $572.78 | 11,422 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-08 | 1,125 | $573.98 | 10,297 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-08 | 3,173 | $575.02 | 7,124 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-08 | 412 | $575.80 | 6,712 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (right-to-buy) | Disposition | 2024-02-08 | 1,612 | $0.00 | 1,612 | $62.00 |
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2024-02-08 | 8,198 | $0.00 | 8,198 | $62.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-02-13 | No | 4 | M | Direct | |
| 0 | 2024-02-13 | No | 4 | M | Direct |
Footnotes
- Represents the weighted average price of the shares sold ranging from a low of $571.50 to a high of $572.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $572.525 to a high of $573.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $573.58 to a high of $574.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $574.625 to a high of $575.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $575.78 to a high of $575.845 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Grant of option to buy 806 shares of Issuer common stock that vested in one installment on February 14, 2019, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the 'Stock Split'). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.
- Grant of option to buy 4,099 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.
Billionaire Hedge Funds
